Ligand Pharma (LGND) –
-
Form ARS LIGAND PHARMACEUTICALS For: Dec 31
-
Form DEFA14A LIGAND PHARMACEUTICALS
-
Form DEF 14A LIGAND PHARMACEUTICALS For: Dec 31
-
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
-
Form 8-K LIGAND PHARMACEUTICALS For: Apr 17
-
Ligand Pharma (LGND) Announces New Topiramate Injection Data Presented
-
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
-
Ligand Pharma (LGND) Launches Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
-
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
-
Form 4 LIGAND PHARMACEUTICALS For: Mar 25 Filed by: Davis Todd C
-
Form 4 LIGAND PHARMACEUTICALS For: Mar 05 Filed by: Sabba Stephen L
-
Form 4 LIGAND PHARMACEUTICALS For: Mar 05 Filed by: Aryeh Jason
-
Form 144 LIGAND PHARMACEUTICALS Filed by: Sabba Stephen L
-
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
-
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Form S-8 LIGAND PHARMACEUTICALS
-
Form 4 LIGAND PHARMACEUTICALS For: Feb 27 Filed by: Reardon Andrew
-
Form 4 LIGAND PHARMACEUTICALS For: Feb 27 Filed by: Korenberg Matthew E
-
Form 4 LIGAND PHARMACEUTICALS For: Feb 27 Filed by: Espinoza Octavio
-
Form 4 LIGAND PHARMACEUTICALS For: Feb 27 Filed by: Davis Todd C
-
Form 144/A LIGAND PHARMACEUTICALS Filed by: Espinoza Octavio
-
Form 10-K LIGAND PHARMACEUTICALS For: Dec 31
-
Form 144 LIGAND PHARMACEUTICALS Filed by: Gray Nancy Ryan
-
Form 144 LIGAND PHARMACEUTICALS Filed by: Espinoza Octavio
-
Form 8-K LIGAND PHARMACEUTICALS For: Feb 27
-
Ligand Pharma (LGND) Tops Q4 EPS by 39c ; Offers Guidance
-
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
-
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
-
Form 4 LIGAND PHARMACEUTICALS For: Feb 15 Filed by: Korenberg Matthew E
-
Form 4 LIGAND PHARMACEUTICALS For: Feb 15 Filed by: Reardon Andrew
-
Form 4 LIGAND PHARMACEUTICALS For: Feb 15 Filed by: Davis Todd C
-
Form 4 LIGAND PHARMACEUTICALS For: Feb 15 Filed by: Espinoza Octavio
-
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
-
Form SC 13G LIGAND PHARMACEUTICALS Filed by: MACQUARIE GROUP LTD
-
Form SC 13G/A LIGAND PHARMACEUTICALS Filed by: VANGUARD GROUP INC
-
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
-
Form SC 13G/A LIGAND PHARMACEUTICALS Filed by: JANUS HENDERSON GROUP PLC
-
Form SC 13G LIGAND PHARMACEUTICALS Filed by: GOLDMAN SACHS GROUP INC
-
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Form SC 13G/A LIGAND PHARMACEUTICALS Filed by: BlackRock Inc.
-
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
-
Form 8-K LIGAND PHARMACEUTICALS For: Jan 05
-
Ligand Pharma (LGND) Announces FDA Approval of ZELSUVMI
-
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
-
Form 4 LIGAND PHARMACEUTICALS For: Dec 29 Filed by: Reardon Andrew
-
Form 4 LIGAND PHARMACEUTICALS For: Jan 02 Filed by: Korenberg Matthew E
-
Ligand Pharma (LGND) Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
-
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
-
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
-
Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life
Back to LGND Stock Lookup
